Phase 2b Autoimmune CAR-T Win
Congratulations to Cartesian Therapeutics on their Phase 2b autoimmune CAR-T trial success—shifting the intensity of the cell therapy paradigm! This milestone is a testament to their innovation. It’s exciting to see mRNA as part of that approach, stirring hope for those suffering from autoimmunity.
READ MORE
Accelerating LNP Development for mRNA Delivery Using AGILE
In a world where the potential of mRNA medicines is partially constrained by the ability to functionally deliver mRNA payloads to the right cells, this study shows that artificial intelligence, in the form of deep-learning, can accelerate the discovery of novel lipid nanoparticle chemistries. Further, the approach helps to predict the biological activity of these chemistries which will reduce the reliance on animal studies and speed up the discovery of new LNPs, potentially unlocking new disease targets for mRNA.
READ THE ARTICLE
mRNA Vaccine for Alzheimer’s Disease
This pilot study compares the immunogenicity of potential pDNA to mRNA therapeutic vaccines for Alzheimer’s Disease in mice and non-human primates. The mRNA fares quite well to a clinical pDNA vaccine, creating hope that mRNA may one day play a part in protecting patients suffering from neurodegenerative disease. Vernal is honored to have played a small but important part in this research.
READ THE PAPER
GSK Stepping Up: mRNA Vaccinations
GSK, a British pharmaceutical and biotechnology company, headquartered in London, continues to be enthusiastic about mRNA vaccines.
EXPLORE NOW
New Initiative: mRNA Vaccine Development Against H5N1
The World Health Organization (WHO) and the Medicines Patent Pool (MPP) have launched a new initiative to advance mRNA vaccine development against human avian influenza (H5N1). This project aims to enhance pandemic preparedness by developing vaccine candidates and transferring the technology to low- and middle-income countries. This effort reflects the WHO’s commitment to equitable access to health technologies and strengthening global response capabilities for future pandemics.
LEARN MORE
FDA Guidance: Platform Technology Designation Program for Drug Development
The FDA’s new guidance clarifies eligible Platform Technologies must adhere to the statutory definition and require consistent CMC processes. Applicants can recycle features across products, while those lacking assets can leverage CDMOs like Vernal Biosciences for standardized processes. Vernal’s CEO, Christian Cobaugh, Senior Director Commercial & Technical Operations, Grant Henderson and guest contributor, Khaled Yamout share their thoughts in this blog article.
READ MORE
When Does mRNA Purity Matter?
We want to hear your opinion. When does mRNA purity matter? Answer this open-ended question however you interpret it by submitting this form.
SHARE MY OPINION
